


Investigational Pipeline

We are investigating efgartigimod for the treatment of several autoimmune diseases.

Efgartigimod is marketed as VYVGART for the treatment of generalized myasthenia gravis (gMG) in adult patients and VYVGART Hytrulo for the treatment of gMG and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adult patients.

The agents below are not approved for the uses listed by any regulatory agency as efficacy and safety have not been established.



Neurology Rheumatology Nephrology Endocrinology Hematology

^aAges between 2 and 18. ^bAges between 12 and 18. ^cThe objective is to evaluate the overall long-term safety of efgartigimod alfa, including the occurrence of serious infections, in gMG patients. ^dThe objective is to evaluate the overall long-term safety of efgartigimod alfa in gMG patients treated with efgartigimod alfa compared to gMG patients not exposed to efgartigimod alfa.
Abbreviations: ASyS, antisynthetase syndrome; C2, complement factor 2; DM, dermatomyositis; FcRn, neonatal Fc receptor; IMNM, immune-mediated necrotizing myopathy; MuSK, muscle-specific tyrosine kinase.

Investigational Pipeline

We are evaluating empasiprubarb for the treatment of IgM driven autoimmune diseases.

The agents below are not approved for the uses listed by any regulatory agency as efficacy and safety have not been established.

	Ongoing Clinical Trials	Preclinical	Phase 1	Proof of Concept	Registrational
Empasiprubarb Target: C2	arda Empassion iMMersion varvara emvigorate emnergize				Multifocal Motor Neuropathy (MMN) Delayed Graft Function (DGF) Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Combination	adapt				Generalized Myasthenia Gravis (gMG)
Adimanebart Target: MuSK	CMS PHASE 1B STUDY ARGX-119-2302 CMS NATURAL HISTORY STUDY ARGX-119-NIS-2301 Sparkle spinal muscular atrophy study				Congenital Myasthenic Syndrome (CMS) Congenital Myasthenic Syndrome (CMS) Spinal Muscular Atrophy (SMA)

Neurology

Rheumatology

Nephrology

Endocrinology

Hematology

Abbreviations: ASyS, antisynthetase syndrome; C2, complement factor 2; DM, dermatomyositis; FcRn, neonatal Fc receptor; IMNM, immune-mediated necrotizing myopathy; MuSK, muscle-specific tyrosine kinase.

